James D. Crapo, M.D. Named CEO Of Incara Pharmaceuticals Corp. (INCR)
10/19/2005 5:11:42 PM
More...
|
Incara Pharmaceuticals Corp. (INCR) Announces Adjustment To Phase 1 Clinical Trial Of AEOL 10150 To Initiate Safety Studies Directly In Patients With ALS
10/19/2005 5:11:40 PM
More...
|
Incara Pharmaceuticals Corp. (INCR) Announces Results For Second Quarter Of Fiscal 2004
10/19/2005 5:11:18 PM
More...
|
Incara Pharmaceuticals Corp. (INCR) To Present At The Rodman & Renshaw Techvest Global Healthcare Conference
10/19/2005 5:11:16 PM
More...
|
Incara Pharmaceuticals Corp. (INCR) Submits IND To The FDA To Initiate Human Clinical Trials For Novel Therapeutic Approach For ALS; Announces The Resignation Of Its CEO; And Announces Appointment Of Dr. Shayne Gad As President
10/19/2005 5:11:12 PM
More...
|
Incara Pharmaceuticals Corp. (INCR) Begins Transition To Clinical Development Phase Of Lead Molecule For ALS And Ushers In New Board Of Directors To Manage Transition
10/19/2005 5:11:09 PM
More...
|
Incara Pharmaceuticals Corp. (INCR) Compound Results Presented At American Academy of Neurology Annual Meeting - Update On Clinical Trials
10/19/2005 5:11:03 PM
More...
|
Incara Pharmaceuticals Corp. (INCR) Closes On $10.26 Million Financing
10/19/2005 5:10:57 PM
More...
|
Incara Pharmaceuticals Corp. (INCR) Stockholders Approve Critical Reorganization
10/19/2005 5:10:49 PM
More...
|
Incara Pharmaceuticals Corp. (INCR) Compound Results To Be Presented At 14th International Symposium On ALS/MND
10/19/2005 5:10:48 PM
More...
|
|